Sandra et al. found that activation of Janus kinase 1/2 (JAK1/2)-dependent signal transducer and activator of transcription 3 (STAT3) can mediate the resistance to MEK inhibitors in KRAS-mutant CRC models. Here, KRAS is linked to colorectal carcinoma.